Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.33 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.32 |
| ▸ | CCKBR | P32239 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | NPY2R | P49146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13354666 | 0.83 | CYP3A4 (0.44) | CYP3A4LMNATP53MAPTMEN1 | |
| SCHEMBL426454 | 0.82 | CYP3A4 (0.54) | CYP3A4LMNATP53MAPTMEN1 | |
| SCHEMBL428401 | 0.81 | CYP3A4 (0.42) | CYP3A4LMNATP53MAPTMEN1 | |
| SCHEMBL428313 | 0.79 | CYP3A4 (0.44) | CYP3A4LMNATP53MAPTMEN1 | |
| SCHEMBL427791 | 0.69 | CYP3A4 (0.53) | CYP3A4LMNATP53MAPTMEN1 | |
| SCHEMBL13354633 | 0.68 | CYP3A4 (0.52) | CYP3A4LMNATP53MAPTMEN1 | |
| SCHEMBL426271 | 0.68 | CYP3A4 (0.52) | CYP3A4LMNATP53MAPTMEN1 | |
| SCHEMBL429690 | 0.66 | CYP3A4 (0.50) | CYP3A4LMNATP53MAPTMEN1 | |
| SCHEMBL429691 | 0.65 | CYP3A4 (0.49) | CYP3A4LMNATP53MAPTMEN1 | |
| SCHEMBL10167756 | 0.63 | CYP3A4 (0.52) | CYP3A4LMNATP53MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383654-B2 | Heterocyclic antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383654-B2 | Heterocyclic antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120022119-A1 | HETEROCYCLIC ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022119-A1 | HETEROCYCLIC ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2010057118-A2 | HETEROCYCLIC ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022119-A1 | HETEROCYCLIC ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | CYP3A4 514/4885CYSLTR2 17/4885CYSLTR1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.